• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharmaceutical Executive's 2021 Emerging Pharma Leaders

Pharmaceutical ExecutivePharmaceutical Executive-05-01-2021
Volume 41
Issue 5

Pharm Exec profiles 13 diverse leaders vital to the future of the biopharma industry.

Click on the links below to read the profiles of Pharm Exec's 2021 Emerging Pharma Leaders.

Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D, Schrödinger

Sally Allain, Head of Johnson & Johnson Innovation, LLC – JLABS @ Washington, DC

Daniel Getts, CEO, Myeloid Therapeutics

Simba Gill, PhD, CEO, Evelo Biosciences

Michael Henderson, MD, Chief Business Officer, BridgeBio Pharma

Donna Hunt Hodge, Director, New Product Development, Inherited Retinal Diseases, Johnson & Johnson

John Hoekman, PhD, Co-Founder & Chief Scientific Officer, Impel NeuroPharma

Lukasz Jarzyna, Head of Global Value, Access, and Pricing, Alexion Pharmaceuticals

William “BJ” Jones, Chief Commercial Officer, Migraine & Common Disease, Biohaven Pharmaceuticals

Kirsten Kester, Vice President, Business Development, Obsidian Therapeutics

Carsten Linnemann, PhD, CEO, Neogene Therapeutics

Carla Pearson, Vice President and Global Commercial Lead for Cabotegravir, ViiV Healthcare

Teisha Robinson, Director of Strategic Accounts-Emerging Accounts, Johnson & Johnson Health Care Systems Inc.

*From a pool of over 100 nominations, these final selections were judged in a blinded process by three Editorial Advisory Board members and a former EPL.

Related Videos
Related Content